%0 Journal Article
%T Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment
%A Maria Del Ben
%A Mario Fabiani
%A Lorenzo Loffredo
%A Licia Polimeni
%A Roberto Carnevale
%A Francesco Baratta
%A Marco Brunori
%A Fabiana Albanese
%A Teresa Augelletti
%A Francesco Violi
%A Francesco Angelico
%J BMC Pulmonary Medicine
%D 2012
%I BioMed Central
%R 10.1186/1471-2466-12-36
%X We studied 138 consecutive patients with heavy snoring and possible OSAS. Patients underwent unattended overnight home polysomnography. Ten patients with severe OSAS were revaluated after 6£¿months of nCPAP therapy. To assess oxidative stress in vivo, we measured urinary 8-iso-PGF2¦Á and serum levels of soluble NOX2-derived peptide (sNOX2-dp). Serum levels of nitrite/nitrate (NOx) were also determined. Flow-mediated brachial artery dilation (FMD) was measured to asses endothelial function.Patients with severe OSAS had higher urinary 8-iso-PGF2¦Á (p<0.001) and serum NOX2 and lower NOx. A negative association was observed between FMD and OSA severity. Apnea/hypopnea index was significantly correlated with the indices of central obesity and with urinary 8-isoprostanes (r=0.298, p<0.001). The metabolic syndrome (t=-4.63, p<0.001) and urinary 8-isoprostanes (t=-2.02, p<0.05) were the only independent predictors of FMD. After 6-months nCPAP treatment, a significant decrease of serum NOX2, (p<0.005) and urinary 8-iso-PGF2¦Á (p<0.01) was observed, while serum NOx showed only a minor increase. A statistically significant increase of FMD was observed (from 3.6% to 7.0%).The results of our study indicate that patients with OSAS and cardiometabolic comorbidities have increased oxidative stress and arterial dysfunction that are partially reversed by nCPAP treatment.Obstructive sleep apnoea syndrome (OSAS) is a common nocturnal disorder characterized by the presence of repetitive apnoea and hypopnoea during sleep, daytime sleepiness and cardiopulmonary dysfunction. Patients with OSAS experience recurrent episodes of cessation of breathing which expose the cardiovascular system to cycles of hypoxia, exaggerated negative intrathoracic pressure and arousals [1].The majority of OSAS patients show the cluster of metabolic and non-metabolic cardiovascular risk factors of the metabolic syndrome and it has also suggested that OSA may be a manifestation of metabolic syndrome (MS) [2-4].Severa
%U http://www.biomedcentral.com/1471-2466/12/36